The efficacy of oral isotretinoin versus cyproterone compound in female patients with acne and the triad of cutaneous hyperandrogenism: A randomized clinical trial

Faghihi, Gita; Jamshidi, Kioumars; Tajmirriahi, Nabet; Abtahi-Naeini, Bahareh; Nilforoshzadeh, Mohamadali; Radan, Mohamadreza; Hosseini, Sayed Mohsen

The efficacy of oral isotretinoin versus cyproterone compound in female patients with acne and the triad of cutaneous hyperandrogenism: A randomized clinical trial

Authors

¹ Department of Dermatology, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

² Department of Dermatology, School of Medicine, Ilam University of Medical Sciences, Ilam, Iran

³ Department of Dermatology Center, Noorand Ali Asghar Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: SAHA (Seborrhea, Acne, Hirsutism and Androgenetic Alopecia) syndrome is a dermatologic disorder, with variant response to treatment. Triad of cutaneous hyperandrogenism included nodulocystic or severe acne, female pattern hair loss and hirsutism.
Aim: The aim of this study is to compare the effectiveness of isotretinoin and cyproterone compound in the treatment of nodulocystic acne, in patients with SAHA syndrome or triad of cutaneous hyperandrogenism.
Materials and Methods: 30 female patients with SAHA syndrome were divided randomly into two groups. Group A was treated with cyproterone compound from day 5 of menstrual cycle onwards for 3 weeks and a week without it and group B received isotretinoin, with a dose of 0.75 mg/kg per day from the beginning of menses onwards for 4 months. The results were evaluated by a blind dermatologist using Acne Severity Index (ASI) score at baseline and monthly for 4 months.
Results: Despite a continuous reduction in ASI score in both the groups, according to both physician (P = 0.63) and patient (P = 0.25) assessment, cyproterone compound was not statistically more effective than conventional treatment of nodulocystic acne at the end of the study. Side-effects were reported in patients in both groups, generally being mild and tolerable except in two subjects.
Conclusion: This study indicates that cyproterone compound is not superior to isotretinoin in the treatment of nodulocystic acne in patient with SAHA syndrome or triad of cutaneous hyperandrogenism. Indeed, other studies are needed to evaluate the effect of cyproterone compound (regardless of androgen level) and isotretinoin in subjects with only nodulocystic acne.

Keywords

References

1.	Camacho F. Constitutional hirsutism. The SAHA syndrome. In: Camacho F, Randall VA, Price VH, editors. Hair and its Disorders: Biology, Pathology and Management. London: Martin Dunitz; 2000. p. 359-67.
2.	Capitanio B, Sinagra JL, Bordignon V, Cordiali Fei P, Picardo M, Zouboulis CC. Underestimated clinical features of postadolescent acne. J Am Acad Dermatol 2010;63:782-8.
3.	Camacho F. SAHA syndrome. In: Camacho F, Montagna W, editors. TrichologyDiseases of the Pilosebaceous Follicle. Madrid: Aula Meédica; 1997. p. 673-90.
4.	Acne. In: James WD, Berger TG, Elston D, editors. Andrews' Diseases of the Skin. 11 ^rd ed:china: Elsevier Saunders; 2011. p. 228-46.
5.	Rosenfield RL. What every physician should know about polycystic ovary syndrome. Dermatol Ther 2008;21:354-61.
6.	Landay M, Huang A, Azziz R. Degree of hyperinsulinemia, independent of androgen levels, is an important determinant of the severity of hirsutism in PCOS. Fertil Steril 2009;92:643-7.
7.	George R, Clarke S, Thiboutot D. Hormonal therapy for acne. Semin Cutan Med Surg 2008;27:188-96.
8.	van Wayjen RG, van den Ende A. Experience in the long-term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: Efficacy, metabolic and endocrine effects. Exp Clin Endocrinol Diabetes 1995;103:241-51.
9.	Goldsmith LA, Bolognia JL, Callen JP, Chen SC, Feldman SR, Lim HW, et al.; AmericanAcademyofDermatology. American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: Summary and recommendations. J Am Acad Dermatol 2004;50:900-6.
10.	Pochi PE, Shalita AR, Strauss JS, Webster SB, Cunliffe WJ, Katz HI, et al. Report of the Consensus Conference on Acne Classification. Washington, D.C., March 24 and 25, 1990. J Am Acad Dermatol 1991;24:495-500.
11.	Magin P, Adams J, Heading G, Pond D, Smith W. Psychological sequelae of acne vulgaris: Results of a qualitative study. Can Fam Physician 2006;52:978-9.
12.	Zaenglein AL, Thiboutot DM. Acne vulgaris. In: Bolognia J, Jorizzo J, Schaffer J, editors. Dermatology. 3rd ed. china: Elsevier Saunders. 2012. p. 545-69.
13.	Lee JW, Yoo KH, Park KY, Han TY, Li K, Seo SJ, et al. Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: A randomized, controlled comparative study. Br J Dermatol 2011;164:1369-75.
14.	Ghalamkarpour F, Nasiri S. Isotretinoin in treatment of acne: Its efficacy, side effects, and recurrence rate of disease. Arch Iran Med 2006;9:228-30.
15.	Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, et a.; GlobalAlliancetoImproveOutcomesinAcne. Management of acne: A report from a global alliance to improve outcomes in acne. J Am Acad Dermatol 2003;49(Suppl1):S1-37.
16.	Strauss JS, Krowchuk DP, Leyden JJ, Lucky AW, Shalita AR, Siegfried EC, et al.; American Academy of Dermatology/American Academy of Dermatology Association. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007;56:651-63.
17.	Amichai B, Shemer A, Grunwald MH. Low-dose isotretinoin in the treatment of acne vulgaris. J Am Acad Dermatol 2006;54:644-6.
18.	Sardana K, Garg VK, Sehgal VN, Mahajan S, Bhushan P. Efficacy of fixed low-dose isotretinoin (20 mg, alternate days) with topical clindamycin gel in moderately severe acne vulgaris. J Eur Acad Dermatol Venereol 2009;23:556-60.
19.	Cyrulnik AA, Viola KV, Gewirtzman AJ, Cohen SR. High-dose isotretinoin in acne vulgaris: Improved treatment outcomes and quality of life. Int J Dermatol 2012;51:1123-30.
20.	Tahir CM. Efficacy and adverse effects of systemic isotretinoin therapy. J Pak Assoc Derma 2011;21:38-42.
21.	Orfanos CE. Antiandrogenos endermatologia. Arch Argent Dermatol 1982;32:52-5.
22.	Pazos F, Escobar-Morreale HF, Balsa J, Sancho JM, Varela C. Prospective randomized study comparing the long-acting gonadotropin-releasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism. Fertil Steril 1999;71:122-8.
23.	Arowojolu AO, Gallo MF, Lopez LM, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2009;3:CD004425.
24.	Frangos JE, Alavian CN, Kimball AB. Acne and oral contraceptives: Update on women's health screening guidelines. J Am Acad Dermatol 2008;58:781-6.

Advanced Biomedical Research